Combination systemic therapies with immune checkpoint inhibitors in biliary tract cancer: effective but not enough?

Expert Rev Gastroenterol Hepatol. 2022 Apr;16(4):307-310. doi: 10.1080/17474124.2022.2055548. Epub 2022 Mar 22.

Authors

Alessandro Rizzo¹, Antonio Cusmai¹, Angela Dalia Ricci², Giovanni Brandi², Gennaro Palmiotti¹

Affiliations

¹ Struttura Semplice Dipartimentale di Oncologia Medica per la Presa in Carico Globale del Paziente Oncologico "Don Tonino Bello," I.R.C.C.S. Istituto Tumori "Giovanni Paolo II", Bari, Italy.
² Department of Experimental, Diagnostic and Specialty Medicine, S. Orsola-Malpighi University Hospital, Bologna, Italy.

PMID: 35302426
DOI: 10.1080/17474124.2022.2055548

No abstract available

Keywords: Immunotherapy; biliary tract cancer; cholangiocarcinoma; durvalumab; pembrolizumab.

Publication types

Editorial
Comment

MeSH terms

Biliary Tract Neoplasms* / drug therapy
Combined Modality Therapy
Humans
Immune Checkpoint Inhibitors* / adverse effects
Immunotherapy

Substances

Immune Checkpoint Inhibitors